These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37760449)

  • 61. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
    McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
    [TBL] [Abstract][Full Text] [Related]  

  • 62. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
    Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effector memory cytotoxic CD3
    Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
    Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
    Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
    Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
    El Bairi K; Haynes HR; Blackley E; Fineberg S; Shear J; Turner S; de Freitas JR; Sur D; Amendola LC; Gharib M; Kallala A; Arun I; Azmoudeh-Ardalan F; Fujimoto L; Sua LF; Liu SW; Lien HC; Kirtani P; Balancin M; El Attar H; Guleria P; Yang W; Shash E; Chen IC; Bautista V; Do Prado Moura JF; Rapoport BL; Castaneda C; Spengler E; Acosta-Haab G; Frahm I; Sanchez J; Castillo M; Bouchmaa N; Md Zin RR; Shui R; Onyuma T; Yang W; Husain Z; Willard-Gallo K; Coosemans A; Perez EA; Provenzano E; Ericsson PG; Richardet E; Mehrotra R; Sarancone S; Ehinger A; Rimm DL; Bartlett JMS; Viale G; Denkert C; Hida AI; Sotiriou C; Loibl S; Hewitt SM; Badve S; Symmans WF; Kim RS; Pruneri G; Goel S; Francis PA; Inurrigarro G; Yamaguchi R; Garcia-Rivello H; Horlings H; Afqir S; Salgado R; Adams S; Kok M; Dieci MV; Michiels S; Demaria S; Loi S;
    NPJ Breast Cancer; 2021 Dec; 7(1):150. PubMed ID: 34853355
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
    Stanowska O; Kuczkiewicz-Siemion O; Dębowska M; Olszewski WP; Jagiełło-Gruszfeld A; Tysarowski A; Prochorec-Sobieszek M
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233396
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
    AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
    Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy.
    Agarwal G; Vishvak Chanthar KMM; Katiyar S; Kumari N; Krishnani N; Sabaretnam M; Chand G; Mishra A; Lal P
    World J Surg; 2023 May; 47(5):1238-1246. PubMed ID: 36735048
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer.
    Hayashi K; Nogawa D; Kobayashi M; Asakawa A; Ohata Y; Kitagawa S; Kubota K; Takahashi H; Yamada M; Oda G; Nakagawa T; Uetake H; Onishi I; Kinowaki Y; Kurata M; Kitagawa M; Yamamoto K
    Front Oncol; 2022; 12():901591. PubMed ID: 36132149
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
    Fujii T; Hirakata T; Kurozumi S; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Oyama T; Shirabe K
    In Vivo; 2020; 34(5):2641-2646. PubMed ID: 32871794
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
    [TBL] [Abstract][Full Text] [Related]  

  • 79. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
    He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
    Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.
    Eng J; Thibault G; Luoh SW; Gray JW; Chang YH; Chin K
    Methods Mol Biol; 2020; 2055():521-562. PubMed ID: 31502168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.